<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AUGMENTIN- amoxicillin and clavulanate potassiumÂ tablet, film coatedÂ </strong><br>Cardinal Health<br></p></div>
<h1>AUGMENTINÂ®<br>(amoxicillin/clavulanate potassium)<br>Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd635f12-1f5d-495a-9978-9bc86a28f669"></a><a name="section-1"></a><p></p>
<h1>undefined</h1>
<p class="First"> To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN (amoxicillin/clavulanate potassium) and other antibacterial drugs, AUGMENTIN should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_0ae50863-6d89-437b-80cd-4063786b5528"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Â AUGMENTIN is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the Î²-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. The amoxicillin molecular formula is C<span class="Sub">16</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">5</span>Sâ€¢3H<span class="Sub">2</span>O, and the molecular weight is 419.46. Chemically, amoxicillin is (2<span class="Italics">S,</span>5<span class="Italics">R,</span>6<span class="Italics">R</span>)-6-[(<span class="Italics">R</span>)-(-)-2-Amino-2-(<span class="Italics">p</span>-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as:</p>
<p><img alt="Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b97ac91-9ed6-4cca-a517-fb1c2b3d0e46&amp;name=7b97ac91-9ed6-4cca-a517-fb1c2b3d0e46-01.jpg"></p>
<p> Clavulanic acid is produced by the fermentation of <span class="Italics">Streptomyces clavuligerus </span>. It is a Î²-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of Î²-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated Î²-lactamases frequently responsible for transferred <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> to penicillins and cephalosporins. The clavulanate potassium molecular formula is C<span class="Sub">8</span>H<span class="Sub">8</span>KNO<span class="Sub">5,</span> and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (<span class="Italics">Z</span>)-(2<span class="Italics">R, </span>5<span class="Italics">R</span>)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate, and may be represented structurally as:</p>
<p><img alt="Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b97ac91-9ed6-4cca-a517-fb1c2b3d0e46&amp;name=7b97ac91-9ed6-4cca-a517-fb1c2b3d0e46-02.jpg"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7cef1d0d-75b2-47ae-8e57-691cf4271484"></a><a name="section-2.1"></a><p></p>
<h2>Inactive Ingredients</h2>
<p class="First"> Colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide.</p>
<p> Each tablet of AUGMENTIN contains 0.63Â mEq potassium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_99111ff7-3a4e-4025-95b6-23d0a5c34802"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"> Amoxicillin and clavulanate potassium are well absorbed from the gastrointestinal tract after oral administration of AUGMENTIN. Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While AUGMENTIN can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In 1 study, the relative bioavailability of clavulanate was reduced when AUGMENTIN was dosed at 30 and 150Â minutes after the start of a high-fat breakfast. The safety and efficacy of AUGMENTIN have been established in clinical trials where AUGMENTIN was taken without regard to meals. </p>
<p> Mean<span class="Sup">*</span> amoxicillin and clavulanate potassium pharmacokinetic parameters are shown in the table below:</p>
<a name="id_15f69cd9-e8e2-4916-936b-c75e71d719b0"></a><table width="0.000">
<caption><span></span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"><p class="First">Dose<span class="Sup">â€ </span> and regimen</p></td>
<td class="Toprule" align="center" colspan="2" valign="top"><p class="First">AUC<span class="Sub">0-24</span> (mcgâ€¢hr/mL)</p></td>
<td align="center" colspan="2" valign="top"><p class="First">C<span class="Sub">max</span> (mcg/mL)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First"> amoxicillin/ clavulanate potassium</p></td>
<td align="center" valign="top"><p class="First"> amoxicillin (Â±S.D.)</p></td>
<td align="center" valign="top"><p class="First">clavulanate potassium (Â±S.D.)</p></td>
<td align="center" valign="top"><p class="First"> amoxicillin (Â±S.D.)</p></td>
<td align="center" valign="top"><p class="First">clavulanate potassium (Â±S.D.)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">250/125Â mg q8h</p></td>
<td align="left" valign="top"><p class="First">26.7 Â± 4.56</p></td>
<td align="right" valign="top"><p class="First">12.6 Â± 3.25</p></td>
<td align="right" valign="top"><p class="First">3.3 Â± 1.12</p></td>
<td align="center" valign="top"><p class="First">1.5 Â± 0.70</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">500/125Â mg q12h</p></td>
<td align="left" valign="top"><p class="First">33.4 Â± 6.76</p></td>
<td align="right" valign="top"><p class="First">8.6 Â± 1.95</p></td>
<td align="right" valign="top"><p class="First">6.5 Â± 1.41</p></td>
<td align="center" valign="top"><p class="First">1.8 Â± 0.61</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">500/125Â mg q8h</p></td>
<td align="left" valign="top"><p class="First">53.4 Â± 8.87</p></td>
<td align="right" valign="top"><p class="First">15.7 Â± 3.86</p></td>
<td align="right" valign="top"><p class="First">7.2 Â± 2.26</p></td>
<td align="center" valign="top"><p class="First">2.4 Â± 0.83</p></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><p class="First">875/125Â mg q12h</p></td>
<td align="left" valign="top"><p class="First">53.5 Â± 12.31</p></td>
<td align="right" valign="top"><p class="First">10.2 Â± 3.04</p></td>
<td align="right" valign="top"><p class="First">11.6 Â± 2.78</p></td>
<td align="center" valign="top"><p class="First">2.2 Â± 0.99</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">*</span> Mean values of 14 normal volunteers (nÂ =Â 15 for clavulanate potassium in the low-dose regimens). Peak concentrations occurred approximately 1.5Â hours after the dose.</p>
<p><span class="Sup">â€ </span>Administered at the start of a light meal.</p>
<p> Amoxicillin serum concentrations achieved with AUGMENTIN are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. The half-life of amoxicillin after the oral administration of AUGMENTIN is 1.3 hours and that of clavulanic acid is 1.0Â hour. </p>
<p> Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6Â hours after administration of a single 250-mg or 500-mg tablet of AUGMENTIN.</p>
<p> Concurrent administration of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid. </p>
<p> Neither component in AUGMENTIN is highly protein-bound; clavulanic acid has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound. </p>
<p> Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. The results of experiments involving the administration of clavulanic acid to animals suggest that this compound, like amoxicillin, is well distributed in body tissues. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd2c5465-53c4-4391-bb5a-a345c3783258"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First"> Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Amoxicillin is, however, susceptible to degradation by Î²-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a Î²-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range ofÎ²-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated Î²-lactamases frequently responsible for transferred <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. </p>
<p> The formulation of amoxicillin and clavulanic acid in AUGMENTIN protects amoxicillin from degradation by Î²-lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other Î²-lactam antibiotics. Thus, AUGMENTIN possesses the properties of a broad-spectrum antibiotic and a Î²-lactamase inhibitor. </p>
<p> Amoxicillin/clavulanic acid has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both in vitro and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in INDICATIONS AND USAGE.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8091b797-e722-4418-b732-817d3256dd2f"></a><a name="section-3.1.1"></a><p></p>
<h3>Gram-Positive Aerobes</h3>
<p class="First"><span class="Italics">Staphylococcus aureus</span> (Î²-lactamase and nonâˆ’Î²-lactamaseâˆ’producing)<span class="Sup">â€¡</span></p>
<p><span class="Sup">â€¡</span> Staphylococci which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb47befc-6f2d-4568-84c3-0c2d4c642012"></a><a name="section-3.1.2"></a><p></p>
<h3>Gram-Negative Aerobes</h3>
<p class="First"><span class="Italics">Enterobacter </span> species (Although most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterobacter</span>species are resistant in vitro, clinical efficacy has been demonstrated with AUGMENTIN in <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> caused by these organisms.)</p>
<p><span class="Italics">Escherichia coli</span> (Î²-lactamase and nonâˆ’Î²-lactamaseâˆ’producing)</p>
<p><span class="Italics">Haemophilus influenzae</span> (Î²-lactamase and nonâˆ’Î²-lactamaseâˆ’producing)</p>
<p><span class="Italics">Klebsiella</span> species (All known <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are Î²-lactamaseâˆ’producing.)</p>
<p><span class="Italics">Moraxella catarrhalis</span> (Î²-lactamase and nonâˆ’Î²-lactamaseâˆ’producing)</p>
<p> The following in vitro data are available, <span class="Underline"><span class="Bold">but their clinical significance is unknown</span></span><span class="Underline">. </span></p>
<p> Amoxicillin/clavulanic acid exhibits in vitro minimal inhibitory concentrations (MICs) of 2Â mcg/mL or less against most (â‰¥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae </span><span class="Sup">Â§</span>; MICs of 0.06Â mcg/mL or less against most (â‰¥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Neisseria gonorrhoeae </span>; MICs of 4Â mcg/mL or less against most (â‰¥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of staphylococci and anaerobic bacteria; and MICs of 8Â mcg/mL or less against most (â‰¥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of other listed organisms. However, with the exception of organisms shown to respond to amoxicillin alone, the safety and effectiveness of amoxicillin/clavulanic acid in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<p><span class="Sup">Â§</span> Because amoxicillin has greater in vitro activity against <span class="Italics">S. pneumoniae </span> than does ampicillin or penicillin, the majority of <span class="Italics">S. pneumoniae</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ba72ebd-43de-4329-b3fc-6b3aea98dbaf"></a><a name="section-3.1.3"></a><p></p>
<h3>Gram-Positive Aerobes</h3>
<p class="First"><span class="Italics">Enterococcus faecalis</span><span class="Sup">||</span></p>
<p><span class="Italics">Staphylococcus epidermidis</span> (Î²-lactamase and nonâˆ’Î²-lactamaseâˆ’producing)</p>
<p><span class="Italics">Staphylococcus saprophyticus</span> (Î²-lactamase and nonâˆ’Î²-lactamaseâˆ’producing)</p>
<p><span class="Italics">Streptococcus pneumoniae</span><span class="Sup">|| Â¶</span></p>
<p><span class="Italics">Streptococcus pyogenes</span><span class="Sup">|| Â¶</span></p>
<p>viridans group <span class="Italics">Streptococcus</span><span class="Sup">|| Â¶</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27db9f39-9114-49ff-8702-712a6d27de61"></a><a name="section-3.1.4"></a><p></p>
<h3>Gram-Negative Aerobes</h3>
<p class="First"><span class="Italics">Eikenella corrodens</span> (Î²-lactamase and nonâˆ’Î²-lactamaseâˆ’producing)</p>
<p><span class="Italics">Neisseria gonorrhoeae</span><span class="Sup">â•‘</span> (Î²-lactamase and nonâ€“Î²-lactamaseâ€“producing)</p>
<p><span class="Italics">Proteus mirabilis</span><span class="Sup">â•‘</span> (Î²-lactamase and nonâ€“Î²-lactamaseâ€“producing)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56bd94ea-661c-4ea9-85b5-0d81714563be"></a><a name="section-3.1.5"></a><p></p>
<h3>Anaerobic Bacteria</h3>
<p class="First"><span class="Italics">Bacteroides </span> species, including <span class="Italics">Bacteroides fragilis </span> (Î²-lactamase and nonâ€“Î²-lactamaseâ€“producing)</p>
<p><span class="Italics">Fusobacterium</span> species (Î²-lactamase and nonâ€“Î²-lactamaseâ€“producing)</p>
<p><span class="Italics">Peptostreptococcus</span> species<span class="Sup">Â¶</span></p>
<p><span class="Sup">â•‘</span> Adequate and well-controlled clinical trials have established the effectiveness of amoxicillin alone in treating certain clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these organisms.</p>
<p><span class="Sup">Â¶</span> These are nonâ€“Î²-lactamaseâˆ’producing organisms, and therefore, are susceptible to amoxicillin alone.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e1d0e78-5701-4bee-aae3-cd2d4542557d"></a><a name="section-3.2"></a><p></p>
<h2>Susceptibility Testing</h2>
<p class="First">Â </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dcf1b69a-e594-411b-9509-757b1658d39e"></a><a name="section-3.2.1"></a><p></p>
<h3>Dilution Techniques</h3>
<p class="First"> Quantitative methods are used to determine antimicrobial MICs. These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of amoxicillin/clavulanate potassium powder.</p>
<p> The recommended dilution pattern utilizes a constant amoxicillin/clavulanate potassium ratio of 2 to 1 in all tubes with varying amounts of amoxicillin. MICs are expressed in terms of the amoxicillin concentration in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid. The MIC values should be interpreted according to the following criteria:</p>
<p>RECOMMENDED RANGES FOR AMOXICILLIN/CLAVULANIC ACID SUSCEPTIBILITY TESTING</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_129fa026-1d75-4827-9633-c8699691d5c5"></a><a name="section-3.3"></a><p></p>
<h2>For Gram-Negative Enteric Aerobes</h2>
<a name="id_d947a0d7-b181-47f3-a1aa-d40037bd93c6"></a><table width="0.000">
<caption><span></span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><p class="First"><span class="Underline">MIC (mcg/mL)</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Underline">Interpretation </span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">â‰¤8/4</p></td>
<td align="left" valign="top"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">16/8</p></td>
<td align="left" valign="top"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><p class="First">â‰¥32/16</p></td>
<td align="left" valign="top"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52692030-84ce-40ec-b2d4-01713ef54aab"></a><a name="section-3.4"></a><p></p>
<h2>For Staphylococcus** and Haemophilus species</h2>
<a name="id_2175d8be-585f-4149-a2e5-7baaa8b8709e"></a><table width="0.000">
<caption><span></span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><p class="First"><span class="Underline">MIC (mcg/mL)</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Underline">Interpretation </span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">â‰¤4/2</p></td>
<td align="left" valign="top"><p class="First">Susceptible (S)</p></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><p class="First">â‰¥8/4</p></td>
<td align="left" valign="top"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p class="First"><span class="Sup">**</span> Staphylococci which are susceptible to amoxicillin/clavulanic acid but resistant to methicillin/oxacillin must be considered as resistant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e558ffe8-605a-484a-b4ab-10af1bc93d5d"></a><a name="section-3.5"></a><p></p>
<h2>For S. pneumoniae from non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> sources</h2>
<p class="First"> Isolates should be tested using amoxicillin/clavulanic acid and the following criteria should be used:</p>
<a name="id_68580231-1d86-48e7-a21f-5448482e0758"></a><table width="0.000">
<caption><span></span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><p class="First"><span class="Underline">MIC (mcg/mL)</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Underline">Interpretation </span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">â‰¤2/1</p></td>
<td align="left" valign="top"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">4/2</p></td>
<td align="left" valign="top"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><p class="First">â‰¥8/4</p></td>
<td align="left" valign="top"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE:</span> These interpretive criteria are based on the recommended doses for <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>.</p>
<p> A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p> Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard amoxicillin/clavulanate potassium powder should provide the following MIC values:</p>
<p><span class="Underline">Microorganism</span><span class="Underline">MIC Range (mcg/mL)</span><span class="Underline"><span class="Sup">â€ â€ </span></span></p>
<p><span class="Italics">Escherichia coli</span> ATCC 25922 2 to 8</p>
<p><span class="Italics">Escherichia coli</span> ATCC 35218 4 to 16</p>
<p><span class="Italics">Enterococcus faecalis</span> ATCC 29212 0.25 to 1.0</p>
<p><span class="Italics">Haemophilus influenzae</span> ATCC 49247 2 to 16</p>
<p><span class="Italics">Staphylococcus aureus</span> ATCC 29213 0.12 to 0.5</p>
<p><span class="Italics">Streptococcus pneumoniae</span> ATCC 49619 0.03 to 0.12</p>
<p><span class="Sup">â€ â€ </span> Expressed as concentration of amoxicillin in the presence of clavulanic acid at a constant 2Â parts amoxicillin to 1 part clavulanic acid.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90df7674-0fc4-4cba-8fd2-957e751683d9"></a><a name="section-3.5.1"></a><p></p>
<h3>Diffusion Techniques</h3>
<p class="First"> Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30Â mcg of amoxicillin/clavulanate potassium (20Â mcg amoxicillin plus 10Â mcg clavulanate potassium) to test the susceptibility of microorganisms to amoxicillin/clavulanic acid.</p>
<p> Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-mcg amoxicillin/clavulanate acid (20Â mcg amoxicillin plus 10Â mcg clavulanate potassium) disk should be interpreted according to the following criteria:</p>
<p>RECOMMENDED RANGES FOR AMOXICILLIN/CLAVULANIC ACID SUSCEPTIBILITY TESTING</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_98064c7b-4dbe-4ca7-b637-5801a65213e7"></a><a name="section-3.6"></a><p></p>
<h2>For Staphylococcus â€¡â€¡ species and H. influenzaea</h2>
<a name="id_2a3387b8-fd2e-4b45-91ab-d3d361a942d0"></a><table width="0.000">
<caption><span></span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><p class="First"><span class="Underline">Zone Diameter (mm) </span></p></td>
<td align="left" valign="top"><p class="First"><span class="Underline">Interpretation </span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">â‰¥20</p></td>
<td align="left" valign="top"><p class="First">Susceptible (S)</p></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><p class="First">â‰¤19</p></td>
<td align="left" valign="top"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4db6d1a1-91f9-472e-8fae-fe306e3fdd86"></a><a name="section-3.7"></a><p></p>
<h2>For Other Organisms Except S. pneumoniae and N. gonorrhoea</h2>
<a name="id_84a84e32-eab6-4f32-b28c-147d3e42a59d"></a><table width="0.000">
<caption><span></span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><p class="First"><span class="Underline">Zone Diameter (mm) </span></p></td>
<td align="left" valign="top"><p class="First"><span class="Underline">Interpretation </span></p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">â‰¥18</p></td>
<td align="left" valign="top"><p class="First">Susceptible (S)</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">14 to 17</p></td>
<td align="left" valign="top"><p class="First">Intermediate (I)</p></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><p class="First">â‰¤13</p></td>
<td align="left" valign="top"><p class="First">Resistant (R)</p></td>
</tr>
</tbody>
</table>
<p class="First"><span class="Sup">â€¡â€¡</span> Staphylococci which are resistant to methicillin/oxacillin must be considered as resistant to amoxicillin/clavulanic acid.</p>
<p><span class="Sup">a</span> A broth microdilution method should be used for testing <span class="Italics">H. influenzae</span>. Beta-lactamaseâˆ’negative, ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> must be considered resistant to amoxicillin/clavulanic acid.</p>
<p><span class="Sup">b</span> Susceptibility of <span class="Italics">S. pneumoniae</span> should be determined using a 1-mcg oxacillin disk. Isolates with oxacillin zone sizes of â‰¥20Â mm are susceptible to amoxicillin/clavulanic acid. An amoxicillin/clavulanic acid MIC should be determined on isolates of <span class="Italics">S. pneumoniae</span> with oxacillin zone sizes of â‰¤19Â mm.</p>
<p><span class="Sup">c</span> A broth microdilution method should be used for testing <span class="Italics">N. gonorrhoeae</span> and interpreted according to penicillin breakpoints. </p>
<p> Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for amoxicillin/clavulanic acid.</p>
<p> As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30-mcg amoxicillin/clavulanate potassium (20-mcg amoxicillin plus 10-mcg clavulanate potassium) disk should provide the following zone diameters in these laboratory quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<p><span class="Underline">Microorganism</span><span class="Underline">Zone Diameter (mm)</span></p>
<p><span class="Italics">Escherichia coli </span>ATCC 25922 19 to 25</p>
<p><span class="Italics">Escherichia coli</span> ATCC 35218 18 to 22</p>
<p><span class="Italics">Staphylococcus aureus</span> ATCC 25923 28 to 36</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_14b4773f-4b49-4c0b-a49d-50123bc27a6b"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Â AUGMENTIN is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the conditions listed below:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c319a06c-063f-4731-9162-c105f652543f"></a><a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span></h2>
<p class="First">âˆ’ caused by Î²-lactamaseâˆ’producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H.Â influenzae</span> and <span class="Italics">M. catarrhalis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6950f0a6-0229-4311-b9b2-6ade65442435"></a><a name="section-4.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></h2>
<p class="First">âˆ’ caused by Î²-lactamaseâˆ’producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> and <span class="Italics">M. catarrhalis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56dc5251-d44d-4af1-8970-33b862a678bc"></a><a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></h2>
<p class="First">âˆ’ caused by Î²-lactamaseâˆ’producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> and <span class="Italics">M. catarrhalis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e6a28812-6623-4e77-9e5c-b3903a112804"></a><a name="section-4.4"></a><p></p>
<h2>Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">âˆ’ caused by Î²-lactamaseâˆ’producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">S. aureus</span>, <span class="Italics">E. coli</span>, and <span class="Italics">Klebsiella</span> spp. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_764ff87e-c7ca-49de-83dc-9baeeeec0c8c"></a><a name="section-4.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h2>
<p class="First">âˆ’ caused by Î²-lactamaseâˆ’producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">E. coli</span>, <span class="Italics">KlebsiellaÂ </span>spp., and <span class="Italics">Enterobacter</span> spp. </p>
<p> While AUGMENTIN is indicated only for the conditions listed above, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by ampicillin-susceptible organisms are also amenable to treatment with AUGMENTIN due to its amoxicillin content; therefore, mixed <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by ampicillin-susceptible organisms and Î²-lactamaseâˆ’producing organisms susceptible to AUGMENTIN should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against <span class="Italics">S. pneumoniae </span> than does ampicillin or penicillin, the majority of <span class="Italics">S.Â pneumoniae </span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and AUGMENTIN. (See Microbiology.)</p>
<p> To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN and other antibacterial drugs, AUGMENTIN should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p> Bacteriological studies, to determine the causative organisms and their susceptibility to AUGMENTIN, should be performed together with any indicated surgical procedures. </p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_2eaeabf1-77fe-4d06-bf46-cc951ca0e5b5"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Â AUGMENTIN is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to any penicillin. It is also contraindicated in patients with a previous history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with AUGMENTIN. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_035762fc-31d9-4da5-a7f2-d2385632bc09"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"> SERIOUS AND OCCASIONALLY FATAL <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH AUGMENTIN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> OCCURS, AUGMENTIN SHOULD BE DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED. <span class="Bold">SERIOUS <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLACTIC REACTIONS</span> REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.</span></p>
<p><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including AUGMENTIN, and has ranged in severity from mild to life-threatening; therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents. </span></p>
<p> Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile</span> is one primary cause ofâ€œantibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.â€?</p>
<p> After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, appropriate therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <span class="Italics">C. difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. </p>
<p>Â AUGMENTIN should be used with caution in patients with evidence of hepatic dysfunction. Hepatic toxicity associated with the use of AUGMENTIN is usually reversible. On rare occasions, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported (less than 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications. (See CONTRAINDICATIONS and ADVERSE REACTIONS: Liver.) </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_4de673a7-fd98-4acb-a53e-2f4c978886f4"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_99e828d4-09a8-45ab-84da-fa8cf666835e"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"> While AUGMENTIN possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable during prolonged therapy. </p>
<p> A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. Thus, ampicillin-class antibiotics should not be administered to patients with mononucleosis.</p>
<p> The possibility of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> with mycotic or bacterial pathogens should be kept in mind during therapy. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur (usually involving <span class="Italics">Pseudomonas </span> or <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>), the drug should be discontinued and/or appropriate therapy instituted. </p>
<p> Prescribing AUGMENTIN in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_05d13bf1-4861-4613-8ff9-a0de2ae67e19"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"> Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with AUGMENTIN may result in increased and prolonged blood levels of amoxicillin. Coadministration of probenecid cannot be recommended. </p>
<p> The concurrent administration of allopurinol and ampicillin increases substantially the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> is due to allopurinol or the <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> present in these patients. There are no data with AUGMENTIN and allopurinol administered concurrently.</p>
<p> In common with other broad-spectrum antibiotics, AUGMENTIN may reduce the efficacy of oral contraceptives. </p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_fadd1be9-cf95-4379-bf2b-e12f5432fcc1"></a><a name="section-7.3"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First"> Oral administration of AUGMENTIN will result in high urine concentrations of amoxicillin. High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST<span class="Sup">Â®</span>, Benedictâ€™s Solution, or Fehlingâ€™s Solution. Since this effect may also occur with amoxicillin and therefore AUGMENTIN, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX<span class="Sup">Â®</span>) be used. </p>
<p> Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with amoxicillin and therefore AUGMENTIN. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_44815ba9-6405-4d6b-8b33-b6238fc3e967"></a><a name="section-7.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Â Patients should be counseled that antibacterial drugs including AUGMENTIN, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When AUGMENTIN is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by AUGMENTIN or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_bb41257a-1807-4cb9-9b43-0b885f538bf6"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Â Long-term studies in animals have not been performed to evaluate carcinogenic potential. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cbaca6ed-0f44-49d5-a5ef-60da77c8919f"></a><a name="section-7.5.1"></a><p></p>
<h3>Mutagenesis</h3>
<p class="First"> The mutagenic potential of AUGMENTIN was investigated in vitro with an Ames test, a human lymphocyte cytogenetic assay, a yeast test and a mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay, and in vivo with mouse micronucleus tests and a dominant lethal test. All were negative apart from the in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay where weak activity was found at very high, cytotoxic concentrations.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_8501da50-c2a9-468e-9f17-e4ecc91f1225"></a><a name="section-7.5.2"></a><p></p>
<h3>Impairment of Fertility</h3>
<p class="First"><span class="Bold">Â </span>AUGMENTIN at oral doses of up to 1,200Â mg/kg/day (5.7Â times the maximum human dose, 1,480Â mg/m<span class="Sup">2</span>/day, based on body surface area) was found to have no effect on fertility and reproductive performance in rats, dosed with a 2:1 ratio formulation of amoxicillin:clavulanate.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_c8b6d8cc-edf8-4837-9bf4-4f8dbe1c30fb"></a><a name="section-7.5.3"></a><p></p>
<h3>Teratogenic effects</h3>
<p class="First">Â Pregnancy (Category B). Reproduction studies performed in pregnant rats and mice given AUGMENTIN at oral dosages up to 1,200Â mg/kg/day, equivalent to 7,200 and 4,080Â mg/m<span class="Sup">2</span>/day, respectively (4.9 and 2.8Â times the maximum human oral dose based on body surface area), revealed no evidence of harm to the fetus due to AUGMENTIN. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_cb0af369-32aa-4e51-9f97-0696fb689925"></a><a name="section-7.6"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Â Oral ampicillin-class antibiotics are generally poorly absorbed during labor. Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions; however, it is not known whether the use of AUGMENTIN in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary. In a single study in women with premature rupture of fetal membranes, it was reported that <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment with AUGMENTIN may be associated with an increased risk of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> in neonates. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4629c541-0eaf-4a2c-9747-124aa25d28ef"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"> Ampicillin-class antibiotics are excreted in the milk; therefore, caution should be exercised when AUGMENTIN is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ffffe1eb-29a2-40ba-9418-2ce550fedd93"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Â Pediatric patients weighing 40Â kg or more should be dosed according to the adult recommendations (see DOSAGE AND ADMINISTRATION: Pediatric Patients). Safety and effectiveness of AUGMENTIN Tablets in pediatric patients weighing less than 40 kg have not been established. (See prescribing information for AUGMENTIN Powder for Oral Suspension and Chewable Tablets.)</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_4a0057bc-5902-4213-a697-0dcf229cb0d6"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Â An analysis of clinical studies of AUGMENTIN was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. Of the 3,119 patients in this analysis, 68% were &lt;65 years old, 32% were â‰¥65 years old and 14% were â‰¥75 years old.Â This analysis and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.</p>
<p> This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_acd3eda6-feb3-43c9-87ab-2600339bd46f"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Â AUGMENTIN is generally well tolerated. The majority of side effects observed in clinical trials were of a mild and transient nature and less than 3% of patients discontinued therapy because of drug-related side effects. The most frequently reported adverse effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (9%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (3%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1%) and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (1%). The overall incidence of side effects, and in particular <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, increased with the higher recommended dose. Other less frequently reported reactions include: <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. </p>
<p>The following adverse reactions have been reported for ampicillin-class antibiotics: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c23b6130-a6b3-4ea7-b483-fd9066ee5fed"></a><a name="section-8.1"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, black â€œhairyâ€? tongue, <span class="product-label-link" type="condition" conceptid="4104522" conceptname="Mucocutaneous candidiasis">mucocutaneous candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and hemorrhagic/<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment. (See WARNINGS.) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4dd598fd-f93c-4023-84c9-8e802926449a"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, serum sicknessâˆ’like reactions (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and frequently <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (rarely <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>), <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, and an occasional case of <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> (including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have been reported. These reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, the drug should be discontinued, unless the opinion of the physician dictates otherwise. Serious and occasional fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions can occur with oral penicillin. (See WARNINGS.) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa6c53a4-9108-4564-a046-e95cfc0909d6"></a><a name="section-8.3"></a><p></p>
<h2>Liver</h2>
<p class="First"> A moderate rise in AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) and/or ALT (SGPT) has been noted in patients treated with ampicillin-class antibiotics but the significance of these findings is unknown. Hepatic dysfunction, including increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been infrequently reported with AUGMENTIN. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. On rare occasions, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported (less than 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_853714fa-6864-499c-856b-02a48fd48d8c"></a><a name="section-8.4"></a><p></p>
<h2>Renal</h2>
<p class="First">Â Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> have been reported rarely. <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> has also been reported <span class="Bold">(see OVERDOSAGE)</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4d8b5648-0dba-4f9b-a732-6a3c3a1c5474"></a><a name="section-8.5"></a><p></p>
<h2>Hemic and Lymphatic Systems</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> phenomena. A slight <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> was noted in less than 1% of the patients treated with AUGMENTIN. There have been reports of increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving AUGMENTIN and anticoagulant therapy concomitantly. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88adb9d0-bd30-48f7-aaf9-0d8550bf5777"></a><a name="section-8.6"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, behavioral changes, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> have been reported rarely. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75cea5f1-a391-4cd8-ab6d-98d25692685e"></a><a name="section-8.7"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> (brown, yellow, or gray staining) has been rarely reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_10bf7f48-1264-4aab-bde7-be305811ea5c"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"> Following overdosage, patients have experienced primarily <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> including stomach and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> have also been observed in a small number of patients.</p>
<p> In the case of overdosage, discontinue AUGMENTIN, treat symptomatically, and institute supportive measures as required. If the overdosage is very recent and there is no contraindication, an attempt at <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or other means of removal of drug from the stomach may be performed. A prospective study of 51 pediatric patients at a poison center suggested that overdosages of less than 250Â mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying.<span class="Sup">3</span></p>
<p> Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> resulting in oliguric <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has been reported in a small number of patients after overdosage with amoxicillin. </p>
<p> <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span>, in some cases leading to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> should be maintained to reduce the risk of amoxicillin <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.</p>
<p> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> because of decreased renal clearance of both amoxicillin and clavulanate. Both amoxicillin and clavulanate are removed from the circulation by hemodialysis. (See DOSAGE AND ADMINISTRATION for recommended dosing for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.) </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_9845f09b-8c4d-4ffb-a012-fdd407e8cf54"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"> Since both the 250-mg and 500-mg tablets of AUGMENTIN contain the same amount of clavulanic acid (125Â mg, as the potassium salt), two 250-mg tablets of AUGMENTIN are not equivalent to one 500-mg tablet of AUGMENTIN; therefore, two 250-mg tablets of AUGMENTIN should not be substituted for one 500-mg tablet of AUGMENTIN.</span></p>
<p><span class="Bold">Dosage</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de697f00-d328-48aa-b430-6cd555b6ed72"></a><a name="section-10.1"></a><p></p>
<h2>Adults</h2>
<p class="First">Â The usual adult dose is one 500-mg tablet of AUGMENTIN every 12Â hours or one 250-mg tablet of AUGMENTIN every 8Â hours. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the respiratory tract, the dose should be one 875-mg tablet of AUGMENTIN every 12Â hours or one 500-mg tablet of AUGMENTIN every 8Â hours.</p>
<p> Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> do not generally require a reduction in dose unless the impairment is severe. Severely impaired patients with a glomerular filtration rate of &lt;30Â mL/min. should not receive the 875<span class="Bold">-</span>mg tablet. Patients with a glomerular filtration rate of 10 to 30Â mL/min. should receive 500Â mg or 250Â mg every 12Â hours, depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients with a less than 10Â mL/min. glomerular filtration rate should receive 500Â mg or 250 mg every 24 hours, depending on severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p> Hemodialysis patients should receive 500Â mg or 250Â mg every 24Â hours, depending on severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. They should receive an additional dose both during and at the end of dialysis.</p>
<p> Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals. (See WARNINGS.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fb46850-0389-48e8-9ca9-32dc3539afac"></a><a name="section-10.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First"> Pediatric patients weighing 40Â kg or more should be dosed according to the adult recommendations.</p>
<p><span class="Bold"> Due to the different amoxicillin to clavulanic acid ratios in the 250-mg tablet of AUGMENTIN (250/125) versus the 250-mg chewable tablet of AUGMENTIN (250/62.5), the 250-mg tablet of AUGMENTIN should not be used until the pediatric patient weighs at least 40Â kg or more.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_320be2fb-83aa-40bc-9904-26ccba6e2c19"></a><a name="section-10.2.1"></a><p></p>
<h3>Administration</h3>
<p class="First"> AUGMENTIN may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when AUGMENTIN is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, AUGMENTIN should be taken at the start of a meal.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_2457abb2-06e0-415c-8079-d77cf320f762"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a08529e-c440-437e-930e-3233b87fe0fb"></a><a name="section-11.1"></a><p></p>
<h2>AUGMENTIN 250-mg Tablets</h2>
<p class="First"> Each white oval filmcoated tablet, debossed with AUGMENTIN on 1 side and 250/125 on the other side, contains 250Â mg amoxicillin as the trihydrate and 125Â mg clavulanic acid as the potassium salt.</p>
<p>NDC 0029-6075-27 bottles of 30</p>
<p>NDC 0029-6075-31 Unit Dose (10x10) 100 tablets</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa61568a-1d30-4a17-850e-71ed0174590e"></a><a name="section-11.2"></a><p></p>
<h2>AUGMENTIN 500-mg Tablets</h2>
<p class="First"> Each white oval filmcoated tablet, debossed with AUGMENTIN on 1 side and 500/125 on the other side, contains 500Â mg amoxicillin as the trihydrate and 125Â mg clavulanic acid as the potassium salt.</p>
<p>NDC 0029-6080-12 bottles of 20</p>
<p>NDC 0029-6080-31 Unit Dose (10x10) 100 tablets</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a09029e-bae0-4feb-a2fc-f19cadd626d9"></a><a name="section-11.3"></a><p></p>
<h2>AUGMENTIN 875-mg Tablets</h2>
<p class="First"> Each scored white capsule-shaped tablet, debossed with AUGMENTIN 875 on 1 side and scored on the other side, contains 875Â mg amoxicillin as the trihydrate and 125Â mg clavulanic acid as the potassium salt.</p>
<p>NDC 0029-6086-12 bottles of 20</p>
<p>NDC 0029-6086-21 Unit Dose (10x10) 100 tablets</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8396b74-a30c-4834-b368-f9c229b043d1"></a><a name="section-11.4"></a><p></p>
<h2>AUGMENTIN is Also Supplied as</h2>
<p class="First"> AUGMENTIN 125Â mg/5 mL (125Â mg amoxicillin/31.25Â mg clavulanic acid) For Oral Suspension:</p>
<p>NDC 0029-6085-39 75 mL bottle</p>
<p>NDC 0029-6085-23 100 mL bottle</p>
<p>NDC 0029-6085-22 150 mL bottle</p>
<p> AUGMENTIN 200Â mg/5Â mL (200Â mg amoxicillin/28.5Â mg clavulanic acid) For Oral Suspension:</p>
<p>NDC 0029-6087-29 50 mL bottle</p>
<p>NDC 0029-6087-39 75 mL bottle</p>
<p>NDC 0029-6087-51 100 mL bottle</p>
<p> AUGMENTIN 250Â mg/5Â mL (250Â mg amoxicillin/62.5Â mg clavulanic acid) For Oral Suspension:</p>
<p>NDC 0029-6090-39 75Â mL bottle</p>
<p>NDC 0029-6090-23 100Â mL bottle</p>
<p>NDC 0029-6090-22 150Â mL bottle</p>
<p> AUGMENTIN 400Â mg/5Â mL (400Â mg amoxicillin/57Â mg clavulanic acid) For Oral Suspension:</p>
<p>NDC 0029-6092-29 50Â mL bottle</p>
<p>NDC 0029-6092-39 75Â mL bottle</p>
<p>NDC 0029-6092-51 100Â mL bottle</p>
<p> AUGMENTIN 125Â mg (125Â mg amoxicillin/31.25Â mg clavulanic acid) Chewable Tablets:</p>
<p>NDC 0029-6073-47 carton of 30 (5x6) tablets</p>
<p> AUGMENTIN 200 mg (200Â mg amoxicillin/28.5Â mg clavulanic acid) Chewable Tablets:</p>
<p>NDC 0029-6071-12 carton of 20 tablets</p>
<p> AUGMENTIN 250 mg (250Â mg amoxicillin/62.5Â mg clavulanic acid) Chewable Tablets:</p>
<p>NDC 0029-6074-47 carton of 30 (5x6) tablets</p>
<p> AUGMENTIN 400 mg (400Â mg amoxicillin/57.0Â mg clavulanic acid) Chewable Tablets:</p>
<p>NDC 0029-6072-12 carton of 20 tablets</p>
<p> Store tablets and dry powder at or below 25Â°C (77Â°F). Dispense in original container.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_7f11dc67-cad0-4c53-a534-09d25512cf14"></a><a name="section-12"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"> Data from 2 pivotal studies in 1,191 patients treated for either <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span> or complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> compared a regimen of 875-mg tablets of AUGMENTIN q12h to 500-mg tablets of AUGMENTIN dosed q8h (584 and 607 patients, respectively). Comparable efficacy was demonstrated between the q12h and q8h dosing regimens. There was no significant difference in the percentage of adverse events in each group. The most frequently reported adverse event was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; incidence rates were similar for the 875-mg q12h and 500-mg q8h dosing regimens (14.9% and 14.3%, respectively); however, there was a statistically significant difference (p&lt;0.05) in rates of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or withdrawals with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> between the regimens: 1.0% for 875-mg q12h dosing versus 2.5% for the 500-mg q8h dosing.</p>
<p> In 1 of these pivotal studies, 629 patients with either <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span> or a complicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (i.e., patients with abnormalities of the urinary tract that predispose to relapse of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">bacteriuria</span> following eradication) were randomized to receive either 875-mg tablets of AUGMENTIN q12h or 500-mg tablets of AUGMENTIN q8h in the following distribution:</p>
<p><span class="Underline"><span class="Bold">875Â mg q12h</span></span><span class="Underline"><span class="Bold">500Â mg q8h</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">Pyelonephritis</span> 173 patients 188 patients</p>
<p>Complicated UTI 135 patients 133 patients</p>
<p>Total patients 308 321</p>
<p> The number of bacteriologically evaluable patients was comparable between the 2 dosing regimens. AUGMENTIN produced comparable bacteriological success rates in patients assessed 2 to 4 days immediately following end of therapy. The bacteriologic efficacy rates were comparable at 1 of the follow-up visits (5 to 9 days post-therapy) and at a late post-therapy visit (in the majority of cases, this was 2 to 4 weeks post-therapy), as seen in the table below:</p>
<p><span class="Underline"><span class="Bold">875Â mg q12h</span></span><span class="Underline"><span class="Bold">500Â mg q8h</span></span></p>
<p>2 to 4 days 81%, nÂ =Â 58 80%, nÂ =Â 54</p>
<p>5 to 9 days 58.5%, nÂ =Â 41 51.9%, nÂ =Â 52</p>
<p>2 to 4 weeks 52.5%, nÂ =Â 101 54.8%, nÂ =Â 104</p>
<p> As noted before, though there was no significant difference in the percentage of adverse events in each group, there was a statistically significant difference in rates of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or withdrawals with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> between the regimens.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_0e1f874e-6020-48e6-8e44-fcd3dce7acad"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25. NCCLS, Villanova, PA, December 1993.</li>
<li>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests - Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24. NCCLS, Villanova, PA, December 1993.</li>
<li>Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. <span class="Italics">Vet Hum Toxicol.</span> 1988;30:66-67.</li>
</ol>
<p class="First">AUGMENTIN is a registered trademark of GlaxoSmithKline.</p>
<p>CLINITEST is a registered trademark of Miles, Inc.</p>
<p>CLINISTIX is a registered trademark of Bayer Corporation.</p>
<p>INSERT GSK</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Â©2005, GlaxoSmithKline. All rights reserved.</p>
<p>August 2005 AG:AL14</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d80da01b-27a2-483f-92a9-d3c827a4ded2"></a><a name="section-14"></a><p></p>
<h1>Principal Display Panel - 500 mg Bag</h1>
<p class="First">Augmentin<span class="Sup">Â®</span></p>
<p>(amoxicillin/clavulanate potassium)</p>
<p>500 mg</p>
<p>10 Tablets</p>
<div class="Figure"><img alt="Bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b97ac91-9ed6-4cca-a517-fb1c2b3d0e46&amp;name=7b97ac91-9ed6-4cca-a517-fb1c2b3d0e46-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AUGMENTINÂ 		
					</strong><br><span class="contentTableReg">amoxicillin and clavulanate potassium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-4511(NDC:0029-6080)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>amoxicillin</strong> (amoxicillin) </td>
<td class="formItem">amoxicillin</td>
<td class="formItem">500Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>clavulanate potassium</strong> (clavulanic acid) </td>
<td class="formItem">clavulanate potassium</td>
<td class="formItem">125Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AUGMENTIN;500;125</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-4511-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050564</td>
<td class="formItem">08/06/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7b97ac91-9ed6-4cca-a517-fb1c2b3d0e46</div>
<div>Set id: 7b97ac91-9ed6-4cca-a517-fb1c2b3d0e46</div>
<div>Version: 1</div>
<div>Effective Time: 20110524</div>
</div>
</div>Â <div class="DistributorName">Cardinal Health</div></p>
</body></html>
